Skip to main
PAVM

PAVmed (PAVM) Stock Forecast & Price Target

PAVmed (PAVM) Analyst Ratings

Based on 1 analyst ratings
Strong Buy
Strong Buy 100%
Buy 0%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

PAVmed Inc. has demonstrated a steady increase in its EsoGuard test processing, moving from 2,756 tests in Q2 to 2,841 in Q3, highlighting the growing demand for its diagnostic offerings. The company’s current valuation is seen as attractive, particularly given its anticipated growth trajectory in 2025 and 2026 for its product lines, which include EsoGuard and esocheck. Additionally, the positive sentiment around the company's pipeline of products aligns with the assessment that it offers substantial upside potential relative to its inherent risks.

Bears say

PAVmed Inc reported a pro forma net loss of $0.8 million with an earnings per share (EPS) of $(0.05), falling short of both internal and consensus estimates, highlighting ongoing financial struggles. Additionally, there has been a consistent decline in the number of EsoGuard tests processed, with Q2 figures showing a decrease to 2,756 tests from 3,034 tests in Q1, indicating potential issues with demand and market traction. The company's early-stage commercialization status for its Lucid business and the Veris platform, coupled with significant risks related to balance sheet liquidity, regulatory approvals, and market competition, contribute to a fundamentally negative outlook for its stock.

PAVmed (PAVM) has been analyzed by 1 analysts, with a consensus rating of Strong Buy. 100% of analysts recommend a Strong Buy, 0% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of PAVmed and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About PAVmed (PAVM) Forecast

Analysts have given PAVmed (PAVM) a Strong Buy based on their latest research and market trends.

According to 1 analysts, PAVmed (PAVM) has a Strong Buy consensus rating as of Jan 28, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $17, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $17, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

PAVmed (PAVM)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.